Meet ADCendo

Founding team

Henrik Stage
Henrik StageCEO

CEO and co-founder Henrik Stage is an experienced biotech-entrepreneur, active in several biotech companies, and was previously CEO/CFO of Santaris Pharma which was acquired by Roche in 2014.

Niels Behrendt, PhD, DSc
Niels Behrendt, PhD, DScCSO

CSO and co-founder Niels Behrendt is a Doctor of Science and PhD from the University of Copenhagen. He has been active in cancer research for more than 20 years and has particular expertise in the structure, function and targeting of receptors engaged in cancer invasion. He has longstanding experience in research leadership and has supervised a major part of the scientific work that enables the cancer targeting strategy of ADCendo.

Lars Henning Engelholm, PhD
Lars Henning Engelholm, PhDCRO/COO

CRO/COO and co-founder Lars H. Engelholm got his PhD in biochemistry from University of Copenhagen in 2001, and today he is a group leader at The Finsen Laboratory. Already early in his career he focused on cancer research, and the continued work in this field has given him an extensive knowledge about cancer pathology and cancer models. The work with cancer models and studies on patient material has been a keystone to develop the targeting strategy used by ADCendo.

Christoffer Nielsen, PhD
Christoffer Nielsen, PhDCTO

Project manager, CTO and co-founder Christoffer F. Nielsen got his PhD in nanomedicine from the iNANO center at Aarhus University in 2012, having worked on development of methods for antibody-mediated delivery of RNA-based medicine. He then moved to The Finsen Laboratory in Copenhagen, where he helped establish and since then carry out the scientific project on utilization of certain receptors for targeted drug delivery by ADCs, that would eventually form the scientific backbone of ADCendo.

ADCendo team members

Jette Lange, PhD
Jette Lange, PhD

Senior Scientific Project Manager Jette B. Lange joined ADCendo in October 2019.

She obtained her PhD in molecular toxicology/cancer biology from the National Research Center for the Working Environment/Faculty of Health Science, University of Copenhagen in 2008. Before joining ADCendo, She worked with understanding the activation and location of cancer-associated proteases, as well as profiling of gene expression patterns using whole genome sequencing in various states from hyper-proliferation to inflammation after exposure to nano-particles.

Sander van Putten, PhD
Sander van Putten, PhD

Senior Scientific Project Manager Sander van Putten joined ADCendo in early 2020.

Sander has a PhD from Uni. of Groningen, and is a former academic colleague from The Finsen Laboratory where we has worked with most of the ADCendo team. Sanders versatile skills makes him a valuable colleague that can participate in both the practical work in laboratory and animal facility, but also manage data and project documentation.

Camilla Dall, MSc
Camilla Dall, MSc

Research Scientist Camilla Dall joined ADCendo in early 2020.

Camilla has an M.Sc. from Uni. of Copenhagen, and a background in neuroscience, that has given her great experience working with rodent models. Camilla currently looks after our experimental animals in a safe and thorough manner.

Joakim N. Sørensen
Joakim N. Sørensen

Joakim N. Sørensen joined ADCendo in late 2019.

Joakim is a 2018 graduate from Copenhagen Business School and University of Copenhagen, specialized in bioentrepreneurship and healthcare innovation. He works as an independent Business Development Consultant with a variety of biotech start-ups in Denmark, especially surrounding COBIS and Bioinnovation Institute.

Meet our advisory board

John M. Lambert. PhD
John M. Lambert. PhD
Consultant/Scientific Advisor
Former CSO and executive at ImmunoGen
Honorary Professor, Queen’s University Belfast, Northern Ireland, UK.

Dr. John Lambert has a longstanding and well recognized history working in the ADC field. In 1982, Dr. Lambert joined the Dana-Farber Cancer Institute, Harvard Medical School, working on the ImmunoGen-funded programs to develop antibody-drug conjugates (ADCs) and immunotoxins as anti-cancer therapeutics, before joining ImmunoGen in 1987. After working in a variety of roles at the company, Dr. Lambert served as Chief Scientific Officer from 2008 until 2015. In 2016, he became a Distinguished Research Fellow at the company until his retirement at the end of 2017. He served on the Executive Committee of the company as Executive Vice President, Research, from 2008 until 2016, followed by a year (2017) on the Executive Committee in an Emeritus capacity until retirement. During Dr Lambert’s tenure in leadership roles at ImmunoGen, the company invented the ADC technology that resulted in the Genentech/Roche drug, Kadcyla®, as well as numerous other ADCs taken into clinical development. One of these is ImmunoGen’s promising drug candidate, mirvetuximab soravtansine, an ADC currently in a phase 3 trial for the treatment of platinum-resistant ovarian cancer. In 2018, he was appointed as an Honorary Professor of Queen’s University Belfast, Northern Ireland, UK.

Vincent de Groot, PhD, CLP
Vincent de Groot, PhD, CLP
Dr. de Groot has a track record in creating and capturing value, as biotech entrepreneur, business development executive and transactor. His profile blends biotech entrepreneurship mentality with hands-on big pharma experience in licensing, acquisitions and venturing. Dr. de Groot founded and led the ADC company Syntarga from inception to exit (Trade Sale). Syntarga discovered and developed [vic-]trastuzumab duocarmazine (SYD985), an ADC drug candidate currently in Phase 3 clinical development.
Murray Yule, MD
Murray Yule, MD
Murray Yule is a UK certified oncologist trained in Addenbrookes Hospital Cambridge and the Texas Medical Center with more than eighteen years experience in the pharma industry with the last ten years spent working in European Biotecnology companies. He has a deep experience in translational oncology and early stage clinical studies of novel biologics including ADCs in solid tumours through his experience at NBE Therapeutics and Axl directed therapies at ADC therapeutics.